Polio Endgame Options: Will We Have the Vaccines Needed?
Answers to frequently asked questions
by Kimberly M. Thompson, The Lancet 2019; doi: 10.1016/S0140-6736(19)31294-2 (published on-line June 4, 2019).
What are the editorial's main findings?
What are the editorial's main recommendations?
Background on polio
What are the editorial’s main findings?
What are the editorial’s main recommendations?
- This editorial provides context about a study published in The Lancet on June 4, 2019 that reported the results of a phase 1 clinical trial of two new oral poliovirus vaccine (OPV) strains for serotype 2 (OPV2).
- Prior Kid Risk modeling suggested substantial potential health and financial benefits of ideal poliovirus vaccine strains for outbreak response, and new OPV (nOPV) strains could also play a role in the event of a global decision to restart OPV production.
- In April-May 2016 all national immunization programs stopped using OPV2 in routine immunization and planned supplemental immunization activities, and in most countries the transmission of serotype 2 live polioviruses died out. However, global cessation of OPV2 use did not proceed as intended everywhere, and outbreaks of serotype-2 circulating vaccine-derived polioviruses led to ten reported paralytic cases in 2019 (as of May 22), following the 71 reported cases in 2018, which exceeded the 33 cases caused by serotype-1 WPV in 2018.
- The more time it takes since mid-2016 to successfully stop all serotype-2 live poliovirus transmission, the higher the risks become of needing to globally restart OPV2 production, and the more urgent the need for better OPV options.
Back to questions
- Given the potential need to restart OPV2 production, the Global Polio Eradication Initiative partners should accelerate efforts to develop at least one new OPV2 strain as quickly as possible.
Back to questions